Clinical Trials
Here you'll find a complete list of current clinical trials near you.
Clinical Trials
Here you'll find a complete list of current clinical trials near you.
Northeast
Massachusetts
| Hospital | Study Title | Trial Link | Status |
|---|---|---|---|
|
Beth Israel Deaconess Medical Center, Boston, MA Dana Farber Cancer Institute, Boston, MA |
A Phase 2 Multicohort Study of Nivolumab in Combination with Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone Sensitive Prostate Cancer Patients with DNA Damage Repair Defects or Inflamed Tumors |
Recruiting |
New Jersey
| Hospital | Study Title | Trial Link | Status |
|---|---|---|---|
|
Memorial Sloan Kettering Cancer Center Basking Ridge, Basking Ridge, NJ Memorial Sloan Kettering Cancer Center Bergen, Montvale, NJ |
A Phase Ib/II Study of Intermittent Talazoparib Plus Temozolomide in Subjects with Metastatic Castration Resistant Prostate Cancer and No Mutations in DNA Damage Repair |
Recruiting |
|
|
Memorial Sloan Kettering Cancer Center Basking Ridge, Basking Ridge, NJ Memorial Sloan Kettering Cancer Center Bergen, Montvale, NJ |
A Phase II Study of Olaparib and Durvalumab in Men with Castration Sensitive Biochemically Recurrent Non Metastatic Prostate Cancer Harboring Mutations in DNA Damage Repair |
Recruiting |
|
|
Memorial Sloan Kettering Cancer Center Basking Ridge, Basking Ridge, NJ Memorial Sloan Kettering Cancer Center Bergen, Montvale, NJ Memorial Sloan Kettering Cancer Center Monmouth, Middletown, NJ |
SAABR: Single Arm Phase II Study of Abiraterone + Atezolizumab + GnRH analog and Stereotactic Body Radiotherapy (SBRT) to the Prostate in Men with Newly Diagnosed Hormone-sensitive Metastatic Prostate Cancer |
Recruiting |
New York
| Hospital | Study Title | Trial Link | Status |
|---|---|---|---|
|
Columbia University Medical Center, New York, NY |
A Multicenter, Open-Label, Parallel, Phase 1b/2a Study of PLX2853 in Combination with Abiraterone Acetate and Prednisone and Phase 1b/2a Study of PLX2853 in Combination with Olaparib in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
Recruiting |
|
|
Memorial Sloan Kettering Cancer Center, New York, NY Memorial Sloan Kettering Cancer Center Commack, Commack, NY Memorial Sloan Kettering Cancer Center Westchester, Harrison, NY |
A Phase II Study of Olaparib and Durvalumab in Men with Castration Sensitive Biochemically Recurrent Non Metastatic Prostate Cancer Harboring Mutations in DNA Damage Repair |
Recruiting |
|
|
Weill Cornell Medical College, New York, NY |
Phase II Trial of Rucaparib in Patients with Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH) |
Recruiting |
|
|
Memorial Sloan Kettering Cancer Center, New York, NY Memorial Sloan Kettering Cancer Center Commack, Commack, NY Memorial Sloan Kettering Cancer Center Westchester, Harrison, NY Memorial Sloan Kettering Cancer Center Nassau, Uniondale, NY |
A Phase Ib/II Study of Intermittent Talazoparib Plus Temozolomide in Subjects with Metastatic Castration Resistant Prostate Cancer and No Mutations in DNA Damage Repair |
Recruiting |
|
|
Weill Cornell Medical College, New York, NY |
A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects |
Recruiting |
|
|
Columbia University Medical Center, New York, NY Memorial Sloan Kettering Cancer Center, New York, NY Memorial Sloan Kettering Cancer Center Commack, Commack, NY Memorial Sloan Kettering Cancer Center Westchester, Harrison, NY Memorial Sloan Kettering Cancer Center Nassau, Uniondale, NY |
SAABR: Single Arm Phase II Study of Abiraterone + Atezolizumab + GnRH analog and Stereotactic Body Radiotherapy (SBRT) to the Prostate in Men with Newly Diagnosed Hormone-sensitive Metastatic Prostate Cancer |
Recruiting |
Pennsylvania
| Hospital | Study Title | Trial Link | Status |
|---|---|---|---|
|
Allegheny Cancer Center, Pittsburgh, Pennsylvania Thomas Jefferson University, Philadelphia, Pennsylvania |
Phase II Study of Olaparib in Men with High-Risk Biochemically-Recurrent Prostate Cancer After Radical Prostatectomy, with Integrated Biomarker Analysis |
Recruiting |
Midwest
Illinois
| Hospital | Study Title | Trial Link | Status |
|---|---|---|---|
|
University of Chicago, Chicago, IL |
A Multicenter, Open-Label, Parallel, Phase 1b/2a Study of PLX2853 in Combination with Abiraterone Acetate and Prednisone and Phase 1b/2a Study of PLX2853 in Combination with Olaparib in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
Recruiting |
|
|
University of Illinois at Chicago, Chicago, IL |
A Phase II Study of Olaparib and Durvalumab in Men with Castration Sensitive Biochemically Recurrent Non Metastatic Prostate Cancer Harboring Mutations in DNA Damage Repair |
Recruiting |
|
|
Kellogg Cancer Center- NorthShore University, Evanston, IL Northwestern Medicine, Chicago, IL Rush University Cancer Center, IL University of Chicago, Chicago, IL |
A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects |
Recruiting |
Indiana
| Hospital | Study Title | Trial Link | Status |
|---|---|---|---|
|
Indiana University/ Melvin and Bren Simon Cancer Center, Indianapolis, IN |
A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects |
Recruiting |
Michigan
| Hospital | Study Title | Trial Link | Status |
|---|---|---|---|
|
Karmanos Cancer Institute, Detroit, MI |
A Multicenter, Open-Label, Parallel, Phase 1b/2a Study of PLX2853 in Combination with Abiraterone Acetate and Prednisone and Phase 1b/2a Study of PLX2853 in Combination with Olaparib in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
Recruiting |
|
|
Karmanos Cancer Institute, Detroit, MI |
A Phase II Study of Olaparib and Durvalumab in Men with Castration Sensitive Biochemically Recurrent Non Metastatic Prostate Cancer Harboring Mutations in DNA Damage Repair |
Recruiting |
|
|
University of Michigan Health System, Ann Arbor, MI |
A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects |
Recruiting |
Minnesota
| Hospital | Study Title | Trial Link | Status |
|---|---|---|---|
|
Mayo Clinic, Rochester, MN |
A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects |
Recruiting |
Missouri
| Hospital | Study Title | Trial Link | Status |
|---|---|---|---|
|
Washington University School of Medicine, Saint Louis, MO |
A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects |
Recruiting |
Nebraska
| Hospital | Study Title | Trial Link | Status |
|---|---|---|---|
|
University of Nebraska Medical Center, Omaha, NE |
Phase II Study of Olaparib in Men with High-Risk Biochemically-Recurrent Prostate Cancer After Radical Prostatectomy, with Integrated Biomarker Analysis |
Recruiting |
Wisconsin
| Hospital | Study Title | Trial Link | Status |
|---|---|---|---|
|
University of Wisconsin, Madison, WI |
A Multicenter, Open-Label, Parallel, Phase 1b/2a Study of PLX2853 in Combination with Abiraterone Acetate and Prednisone and Phase 1b/2a Study of PLX2853 in Combination with Olaparib in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
Recruiting |
|
|
University of Wisconsin, Madison, WI |
A Phase Ib/II Study of Intermittent Talazoparib Plus Temozolomide in Subjects with Metastatic Castration Resistant Prostate Cancer and No Mutations in DNA Damage Repair |
Recruiting |
West
California
| Hospital | Study Title | Trial Link | Status |
|---|---|---|---|
|
City of Hope Comprehensive Cancer Center, Duarte, CA |
A Phase II Study of Olaparib and Durvalumab in Men with Castration Sensitive Biochemically Recurrent Non Metastatic Prostate Cancer Harboring Mutations in DNA Damage Repair |
Recruiting |
|
|
University of California Los Angeles, Los Angeles, CA |
A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects |
Recruiting |
Utah
| Hospital | Study Title | Trial Link | Status |
|---|---|---|---|
|
Huntsman Cancer Institute – University of Utah, Salt Lake City, UT |
A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects |
Recruiting |
Washington State
| Hospital | Study Title | Trial Link | Status |
|---|---|---|---|
|
Fred Hutchinson Cancer Research Center, Seattle, WA |
Durvalumab (MEDI4736) and Olaparib (AZD2281) for treatment of biochemically recurrent prostate cancer in men predicted to have a high neoantigen load: a pilot study |
Recruiting |
South
Florida
| Hospital | Study Title | Trial Link | Status |
|---|---|---|---|
|
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL |
A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects |
Recruiting |
Maryland
| Hospital | Study Title | Trial Link | Status |
|---|---|---|---|
|
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD |
Phase II Study of Olaparib in Men with High-Risk Biochemically-Recurrent Prostate Cancer After Radical Prostatectomy, with Integrated Biomarker Analysis |
Recruiting |
|
|
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD |
Phase II Trial of Rucaparib in Patients with Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH) |
Recruiting |
|
|
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD |
A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects |
Recruiting |
North Carolina
| Hospital | Study Title | Trial Link | Status |
|---|---|---|---|
|
University of North Carolina at Chapel Hill, Chapel Hill, NC |
A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects |
Recruiting |
South Carolina
| Hospital | Study Title | Trial Link | Status |
|---|---|---|---|
|
Carolina Urologic Research Center, Myrtle Beach, SC |
A Multicenter, Open-Label, Parallel, Phase 1b/2a Study of PLX2853 in Combination with Abiraterone Acetate and Prednisone and Phase 1b/2a Study of PLX2853 in Combination with Olaparib in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
Recruiting |
Tennessee
| Hospital | Study Title | Trial Link | Status |
|---|---|---|---|
|
Tennessee Oncology/ Sarah Cannon, Nashville, TN |
A Multicenter, Open-Label, Parallel, Phase 1b/2a Study of PLX2853 in Combination with Abiraterone Acetate and Prednisone and Phase 1b/2a Study of PLX2853 in Combination with Olaparib in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
Recruiting |
Virginia
| Hospital | Study Title | Trial Link | Status |
|---|---|---|---|
|
Virginia Cancer Specialists, Fairfax, VA |
A Multicenter, Open-Label, Parallel, Phase 1b/2a Study of PLX2853 in Combination with Abiraterone Acetate and Prednisone and Phase 1b/2a Study of PLX2853 in Combination with Olaparib in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
Recruiting |
|
|
University of Virginia, Charlottesville, VA |
A Phase Ib/II Study of Intermittent Talazoparib Plus Temozolomide in Subjects with Metastatic Castration Resistant Prostate Cancer and No Mutations in DNA Damage Repair |
Recruiting |
|
|
University of Virginia, Charlottesville, VA |
A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects |
Recruiting |